Most cited papers from Centre François Baclesse

Centre François Baclesse

What are the most cited papers from Centre François Baclesse?

The most cited paper from Centre François Baclesse is "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial" (Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al., 2015), with 6,590 citations. Next come "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (5,563) and "Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers" (2,963).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 286 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet	19 Dec 2015	6,590
2	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access	30 Jan 2012	5,563
3	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers Karoline B. Kuchenbaecker et al. · JAMA Open access	20 Jun 2017	2,963
4	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations A.M. Mandard, Frédéric Dalibard, J.-C. Mandard et al. · Cancer Open access	Jun 1994	2,072
5	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer R. Charles Coombes et al. · New England Journal of Medicine Open access	10 Mar 2004	1,773
6	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Gϋnter von Minckwitz, Marion Jennifer Procter, Evandro de Azambuja et al. · New England Journal of Medicine Open access	5 Jun 2017	1,425
7	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Edward S. Kim, Vera Hirsh, Tony S.K. Mok et al. · The Lancet	Nov 2008	1,246
8	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park et al. · The Lancet Oncology	12 Apr 2016	1,192
9	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet	Mar 2011	1,110
10	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial Gérard Zalcman et al. · The Lancet	22 Dec 2015	980
11	Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial R. Charles Coombes et al. · The Lancet	Feb 2007	914
12	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Amit M. Oza et al. · The Lancet Oncology Open access	24 Jun 2015	875
13	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Karim S. Fizazi et al. · The Lancet Open access	Apr 2022	823
14	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
15	Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors Marie Lange, Florence Joly, Janette L. Vardy et al. · Annals of Oncology Open access	10 Oct 2019	707
16	Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ana Oaknin, Tjalling Bosse, Carien L. Creutzberg et al. · Annals of Oncology Open access	8 Jun 2022	671
17	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer Charles Dolladille, Stéphane Éderhy, Marion Sassier et al. · JAMA Oncology Open access	16 Apr 2020	601
18	Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission Rodrigo Arriagada, T. Le Chevalier, Francoise Borie et al. · JNCI Journal of the National Cancer Institute	Feb 1995	571
19	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial Frédéric Peyrade et al. · The Lancet Oncology	9 Apr 2011	557
20	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial Sylvie Bonvalot et al. · The Lancet Oncology Open access	8 Jul 2019	537
21	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma Corine Bertolotto et al. · Nature 100 authors	18 Oct 2011	529
22	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial Zhihao Lü et al. · BMJ Open access	19 Apr 2022	508
23	ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* David Cibula et al. · International Journal of Gynecological Cancer Open access	May 2023	484
24	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer ABCTB Investigators et al. · Nature Genetics Open access476 authors	23 Oct 2017	477
25	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology	21 Nov 2015	465
26	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial Arnaud Scherpereel et al. · The Lancet Oncology Open access	16 Jan 2019	458
27	Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology	17 Feb 2014	455
28	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease Christophe Fermé et al. · New England Journal of Medicine Open access	7 Nov 2007	448
29	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) Fabrice André, Thomas Bachelot, Frédéric Commo et al. · The Lancet Oncology	6 Feb 2014	418
30	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre et al. · PLoS Medicine Open access	27 Dec 2016	413
31	Cancer of the larynx/hypopharynx, tobacco and alcohol: Iarc international case‐control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France) A. J. TUYNS, Jacques Estève, Luc Raymond et al. · International Journal of Cancer	15 Apr 1988	400
32	Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial Fernanda Mosele et al. · Nature Medicine Open access	24 Jul 2023	392
33	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Fergus J. Couch et al. · PLoS Genetics Open access270 authors	27 Mar 2013	391
34	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Cora Nanette Sternberg et al. · The Lancet Oncology	11 Dec 2014	390
35	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial Jean Bourhis et al. · The Lancet Oncology	18 Jan 2012	388
36	Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial C. Carrié et al. · The Lancet Oncology	8 May 2016	364
37	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies Nicolas Aide, Charline Lasnon, Patrick Veit‐Haibach et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access	16 Jun 2017	361
38	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial Christian Récher et al. · The Lancet Open access	Nov 2011	358
39	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo et al. · JAMA Oncology Open access	23 Jan 2021	353
40	Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer Harry Bleiberg, Thierry Conroy, Bernard Paillot et al. · European Journal of Cancer	Jul 1997	353
41	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial Cecile Le Pechoux, Ariane Dunant, Suresh Senan et al. · The Lancet Oncology	21 Apr 2009	351
42	Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial François‐Clément Bidard et al. · The Lancet Oncology Open access119 authors	29 Sep 2022	349
43	2009 Version of the Chompret Criteria for Li Fraumeni Syndrome Julie Tinat, Gaëlle Bougeard, Stéphanie Baert‐Desurmont et al. · Journal of Clinical Oncology	4 Aug 2009	349
44	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population EMBRACE et al. · Nature Genetics Open access185 authors	19 Sep 2010	344
45	Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial Paul Sargos, Sylvie Chabaud, I. Latorzeff et al. · The Lancet Oncology Open access	28 Sep 2020	336
46	Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis Fiona E. Murray, Nikos Darzentas, Anastasia Hadzidimitriou et al. · Blood Open access	24 Oct 2007	333
47	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up Friedemann U. Honecker et al. · Annals of Oncology Open access	18 Jun 2018	331
48	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study Florence Duffaud, Olivier Mir, Pascaline Boudou‐Rouquette et al. · The Lancet Oncology Open access	23 Nov 2018	329
49	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review Élisabeth Luporsi et al. · Breast Cancer Research and Treatment Open access	2 Nov 2011	326
50	Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891 J.-L. Lefebvre, Guy Andry, Dominique Chevalier et al. · Annals of Oncology Open access	8 Apr 2012	326

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.